Next‐generation agents for fluorescence‐guided glioblastoma surgery

Abstract Glioblastoma is a fast‐growing and aggressive form of brain cancer. Even with maximal treatment, patients show a low median survival and are often subjected to a high recurrence incidence. The currently available treatments require multimodal management, including maximal safe surgical rese...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cristina Chirizzi (Author), Serena Pellegatta (Author), Alessandro Gori (Author), Jacopo Falco (Author), Emanuele Rubiu (Author), Francesco Acerbi (Author), Francesca Baldelli Bombelli (Author)
Formato: Libro
Publicado: Wiley, 2024-05-01T00:00:00Z.
Subjects:
Acceso en liña:Connect to this object online.
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ec3ddecca6d3445f801a9c5c63eb66c0
042 |a dc 
100 1 0 |a Cristina Chirizzi  |e author 
700 1 0 |a Serena Pellegatta  |e author 
700 1 0 |a Alessandro Gori  |e author 
700 1 0 |a Jacopo Falco  |e author 
700 1 0 |a Emanuele Rubiu  |e author 
700 1 0 |a Francesco Acerbi  |e author 
700 1 0 |a Francesca Baldelli Bombelli  |e author 
245 0 0 |a Next‐generation agents for fluorescence‐guided glioblastoma surgery 
260 |b Wiley,   |c 2024-05-01T00:00:00Z. 
500 |a 2380-6761 
500 |a 10.1002/btm2.10608 
520 |a Abstract Glioblastoma is a fast‐growing and aggressive form of brain cancer. Even with maximal treatment, patients show a low median survival and are often subjected to a high recurrence incidence. The currently available treatments require multimodal management, including maximal safe surgical resection, followed by radiation and chemotherapy. Because of the infiltrative glioblastoma nature, intraoperative differentiation of cancer tissue from normal brain parenchyma is very challenging, and this accounts for the low rate of complete tumor resection. For these reasons, clinicians have increasingly used various intraoperative adjuncts to improve surgical results, such as fluorescent agents. However, most of the existing fluorophores show several limitations such as poor selectivity, photostability, photosensitization and high costs. This could limit their application to successfully improve glioblastoma resection. In the present perspective, we highlight the possibility to develop next‐generation fluorescent tools able to more selectively label cancer cells during surgical resection. 
546 |a EN 
690 |a fluorescent‐guided surgery 
690 |a glioblastoma 
690 |a neurosurgery 
690 |a novel fluorescent probes 
690 |a patients' survival 
690 |a Chemical engineering 
690 |a TP155-156 
690 |a Biotechnology 
690 |a TP248.13-248.65 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Bioengineering & Translational Medicine, Vol 9, Iss 3, Pp n/a-n/a (2024) 
787 0 |n https://doi.org/10.1002/btm2.10608 
787 0 |n https://doaj.org/toc/2380-6761 
856 4 1 |u https://doaj.org/article/ec3ddecca6d3445f801a9c5c63eb66c0  |z Connect to this object online.